CNA/
Articles/
2609005319
  • Open Access
  • Review

Stress-Driven Brain Remodeling in Opioid Use Disorder: Toward a Neuroprogressive Model

  • Filippo Della Rocca 1,2,   
  • Icro Maremmani 1,3,*,   
  • Manuel Glauco Carbone 1,4 and 
  • Angelo Giovanni Icro Maremmani 1,3

Received: 15 June 2026 | Revised: 15 September 2026 | Accepted: 30 September 2026 | Published: 26 October 2026

Abstract

Background: Opioid use disorder (OUD) is classically understood through reward dysregulation, opponent processes, and allostatic adaptation, but these models only partly account for the persistent cognitive, affective, and stress-regulatory abnormalities observed in some individuals with long-standing OUD. Methods: This Perspective integrates human evidence from neuroendocrinology, neuroimaging, and neurocognitive research with mechanistic findings from preclinical opioid-exposure and withdrawal models. Throughout the revised framework, direct evidence in humans is distinguished from cross-species mechanistic inference. Results: Repeated opioid exposure induces neuroadaptations that initially compensate for persistent pharmacological perturbation. When exposure is prolonged and accompanied by recurrent intoxication-withdrawal cycling, these adaptations may become increasingly maladaptive and interact with repeated stress-system destabilization. Human studies document abnormalities in hypothalamic-pituitary-adrenal (HPA) axis regulation, brain structure and connectivity, and executive-cognitive functioning in OUD, whereas preclinical studies provide plausible mechanisms involving glucocorticoid and extrahypothalamic corticotropin-releasing factor (CRF) signaling, noradrenergic and dynorphin systems, synaptic plasticity, neuroimmune activation, and cellular stress. We propose a staged continuum from neuroadaptation to maladaptive brain remodeling and, potentially, neuroprogression. At the advanced end of this continuum, we describe a provisional neuroprogressive phenotype characterized by persistent multidomain dysfunction in stress regulation, cognitive-executive processing, affective regulation, and behavioral control beyond acute intoxication or withdrawal in a vulnerable subset of individuals with OUD. Conclusions: The proposed neuroprogressive model defines a testable hypothesis in which cumulative opioid exposure and recurrent withdrawal-related stress burden may contribute to persistent loss of adaptive capacity. Treatment-related stabilization and partial recovery are incorporated into the model, but disease-modifying effects of opioid agonist treatment remain to be demonstrated prospectively. Longitudinal multimodal studies are required to establish the existence, boundaries, prevalence, reversibility, and clinical utility of the proposed phenotype.

Graphical Abstract

Image Viewer
Open in new tab
Download Image

References 

  • 1.

    Di Chiara, G.; Imperato, A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc. Natl. Acad. Sci. USA 1988, 85, 5274–5278. https://doi.org/10.1073/pnas.85.14.5274.

  • 2.

    Burns, J.A.; Kroll, D.S.; Feldman, D.E.; et al. Molecular Imaging of Opioid and Dopamine Systems: Insights Into the Pharmacogenetics of Opioid Use Disorders. Front. Psychiatry 2019, 10, 626. https://doi.org/10.3389/fpsyt.2019.00626.

  • 3.

    Koob, G.F.; Volkow, N.D. Neurobiology of addiction: A neurocircuitry analysis. Lancet Psychiatry 2016, 3, 760–773. https://doi.org/10.1016/s2215-0366(16)00104-8.

  • 4.

    Koob, G.F.; Le Moal, M. Drug Addiction, Dysregulation of Reward, and Allostasis. Neuropsychopharmacology 2001, 24, 97–129. https://doi.org/10.1016/s0893-133x(00)00195-0.

  • 5.

    Koob, G.F. A Role for Brain Stress Systems in Addiction. Neuron 2008, 59, 11–34. https://doi.org/10.1016/j.neuron.2008.06.012.

  • 6.

    Zorrilla, E.P.; Logrip, M.L.; Koob, G.F. Corticotropin releasing factor: A key role in the neurobiology of addiction. Front. Neuroendocrinol. 2014, 35, 234–244. https://doi.org/10.1016/j.yfrne.2014.01.001.

  • 7.

    Goldstein, R.Z.; Volkow, N.D. Dysfunction of the prefrontal cortex in addiction: Neuroimaging findings and clinical implications. Nat. Rev. Neurosci. 2011, 12, 652–669. https://doi.org/10.1038/nrn3119.

  • 8.

    Högberg, J.H.; Philips, B.; Nielsen, J.; et al. Executive function at baseline and follow-up in opioid maintenance patients and its relation to psychiatric comorbidity and substance use patterns. BMC Psychiatry 2025, 25, 396. https://doi.org/10.1186/s12888-025-06524-w.

  • 9.

    Regier, P.S.; Macedo de Arruda, T.C.; Sinko, L.; et al. Factors associated with cognitive flexibility in people with opioid-use disorder: A pilot study. Front. Psychiatry 2024, 15, 1505391. https://doi.org/10.3389/fpsyt.2024.1505391.

  • 10.

    VanDerNagel, J.E.L. Prevalence of cognitive impairment in patients with substance use disorder. Drug Alcohol Rev. 2019, 38, 435–442. https://doi.org/10.1111/dar.12922.

  • 11.

    Jin, L.; Yuan, M.; Zhang, W.; et al. Regional cerebral metabolism alterations and functional connectivity in individuals with opioid use disorder: An integrated resting-state PET/fMRI study. J. Psychiatr. Res. 2024, 169, 126–133. https://doi.org/10.1016/j.jpsychires.2023.11.015.

  • 12.

    Ceceli, A.O.; Huang, Y.; Kronberg, G.; et al. Common and distinct fronto-striatal volumetric changes in heroin and cocaine use disorders. Brain 2023, 146, 1662–1671. https://doi.org/10.1093/brain/awac366.

  • 13.

    Wollman, S.C.; Hauson, A.O.; Hall, M.G.; et al. Neuropsychological functioning in opioid use disorder: A research synthesis and meta-analysis. Am. J. Drug Alcohol Abus. 2019, 45, 11–25. https://doi.org/10.1080/00952990.2018.1517262.

  • 14.

    Gerber, H.; Borgwardt, S.J.; Schmid, O.; et al. The Impact of Diacetylmorphine on Hypothalamic-Pituitary-Adrenal Axis Activity and Heroin Craving in Heroin Dependence. Eur. Addict. Res. 2012, 18, 116–123. https://doi.org/10.1159/000334411.

  • 15.

    Shi, J.; Li, S.X.; Zhang, X.L.; et al. Time-Dependent Neuroendocrine Alterations and Drug Craving during the First Month of Abstinence in Heroin Addicts. Am. J. Drug Alcohol Abus. 2009, 35, 267–272. https://doi.org/10.1080/00952990902933878.

  • 16.

    Kaplan, G.B.; Thompson, B.L. Neuroplasticity of the extended amygdala in opioid withdrawal and prolonged opioid abstinence. Front. Pharmacol. 2023, 14, 1253736. https://doi.org/10.3389/fphar.2023.1253736.

  • 17.

    Kieffer, B.L.; Evans, C.J. Opioid Tolerance–In Search of the Holy Grail. Cell 2002, 108, 587–590. https://doi.org/10.1016/s0092-8674(02)00666-9.

  • 18.

    Christie, M.J. Cellular neuroadaptations to chronic opioids: Tolerance, withdrawal and addiction. Br. J. Pharmacol. 2008, 154, 384–396. https://doi.org/10.1038/bjp.2008.100.

  • 19.

    McEwen, B.S.; Bowles, N.P.; Gray, J.D.; et al. Mechanisms of stress in the brain. Nat. Neurosci. 2015, 18, 1353–1363. https://doi.org/10.1038/nn.4086.

  • 20.

    Seco, M.J.; Waisman Campos, M.; Marzan, N.; et al. Neuroprogression in substance use disorders: Integrating molecular mechanisms, brain circuitry, biomarkers, and implications for clinical staging and service design. Int. Rev. Psychiatry 2026, 1–14. https://doi.org/10.1080/09540261.2026.2683081.

  • 21.

    Bachi, K.; Hurd, Y.L.; Salsitz, E.A. Substance use disorders: A call for a staging paradigm. Transl. Psychiatry 2025, 15, 261. https://doi.org/10.1038/s41398-025-03484-3.

  • 22.

    Kapczinski, F.; Vieta, E.; Andreazza, A.C.; et al. Allostatic load in bipolar disorder: Implications for pathophysiology and treatment. Neurosci. Biobehav. Rev. 2008, 32, 675–692. https://doi.org/10.1016/j.neubiorev.2007.10.005.

  • 23.

    Carbone, M.G.; Maremmani, I.; Della Rocca, F.; et al. From Neuroadaptation to Neuroprogression: Rethinking Chronic Cocaine Exposure Through a Model of Cocaine-Related Cerebropathy. J. Clin. Med. 2026, 15, 2222. https://doi.org/10.3390/jcm15062222.

  • 24.

    Warner, N.S.; Hanson, A.C.; Schulte, P.J.; et al. Prescription Opioids and Longitudinal Changes in Cognitive Function in Older Adults: A Population-Based Observational Study. J. Am. Geriatr. Soc. 2022, 70, 3526–3537. https://doi.org/10.1111/jgs.18030.

  • 25.

    Lu, L.; Yang, W.; Zhang, X.; et al. Potential brain recovery of frontostriatal circuits in heroin users after prolonged abstinence: A preliminary study. J. Psychiatr. Res. 2022, 152, 326–334. https://doi.org/10.1016/j.jpsychires.2022.06.036.

  • 26.

    Butelman, E.R.; Huang, Y.; King, S.G.; et al. Peripheral Blood Cytokines as Markers of Longitudinal Change in White Matter Microstructure Following Inpatient Treatment for Opioid Use Disorders. Biol. Psychiatry Glob. Open Sci. 2025, 5, 100480. https://doi.org/10.1016/j.bpsgos.2025.100480.

  • 27.

    Herman, J.P.; McKlveen, J.M.; Ghosal, S.; et al. Regulation of the Hypothalamic-Pituitary-Adrenocortical Stress Response. Compr. Physiol. 2016, 6, 603–621. https://doi.org/10.1002/j.2040-4603.2016.tb00694.x.

  • 28.

    Lightman, S.L.; Birnie, M.T.; Conway-Campbell, B.L. Dynamics of ACTH and Cortisol Secretion and Implications for Disease. Endocr. Rev. 2020, 41, bnaa002. https://doi.org/10.1210/endrev/bnaa002.

  • 29.

    de Kloet, E.R.; Joëls, M.; Holsboer, F. Stress and the brain: From adaptation to disease. Nat. Rev. Neurosci. 2005, 6, 463–475. https://doi.org/10.1038/nrn1683.

  • 30.

    Androulakis, I.P. Circadian rhythms and the HPA axis: A systems view. WIREs Mech. Dis. 2021, 13, e1518. https://doi.org/10.1002/wsbm.1518.

  • 31.

    Reyes, B.A.S. The Locus Coeruleus: Anatomy, Physiology, and Stress-Related Neuropsychiatric Disorders. Eur. J. Neurosci. 2025, 61, e70111. https://doi.org/10.1111/ejn.70111.

  • 32.

    Arnsten, A.F.T. Stress signalling pathways that impair prefrontal cortex structure and function. Nat. Rev. Neurosci. 2009, 10, 410–422. https://doi.org/10.1038/nrn2648.

  • 33.

    Schwabe, L.; Tegenthoff, M.; Höffken, O.; et al. Simultaneous Glucocorticoid and Noradrenergic Activity Disrupts the Neural Basis of Goal-Directed Action in the Human Brain. J. Neurosci. 2012, 32, 10146–10155. https://doi.org/10.1523/jneurosci.1304-12.2012.

  • 34.

    Koob, G.F.; Buck, C.L.; Cohen, A.; et al. Addiction as a Stress Surfeit Disorder. Neuropharmacology 2014, 76, 370–382. https://doi.org/10.1016/j.neuropharm.2013.05.024.

  • 35.

    Chavkin, C.; Koob, G.F. Dynorphin, Dysphoria, and Dependence: The Stress of Addiction. Neuropsychopharmacology 2016, 41, 373–374. https://doi.org/10.1038/npp.2015.258.

  • 36.

    Bruchas, M.R.; Land, B.B.; Chavkin, C. The dynorphin/kappa opioid system as a modulator of stress-induced and pro-addictive behaviors. Brain Res. 2010, 1314, 44–55. https://doi.org/10.1016/j.brainres.2009.08.062.

  • 37.

    Heilig, M. The NPY system in stress, anxiety and depression. Neuropeptides 2004, 38, 213–224. https://doi.org/10.1016/j.npep.2004.05.002.

  • 38.

    Parsons, L.H.; Hurd, Y.L. Endocannabinoid signalling in reward and addiction. Nat. Rev. Neurosci. 2015, 16, 579–594. https://doi.org/10.1038/nrn4004.

  • 39.

    McEwen, B.S.; Wingfield, J.C. The concept of allostasis in biology and biomedicine. Horm. Behav. 2003, 43, 2–15. https://doi.org/10.1016/s0018-506x(02)00024-7.

  • 40.

    McEwen, B.S.; Gianaros, P.J. Stress- and Allostasis-Induced Brain Plasticity. Annu. Rev. Med. 2011, 62, 431–445. https://doi.org/10.1146/annurev-med-052209-100430.

  • 41.

    Sinha, R. Stress and substance use disorders: Risk, relapse, and treatment outcomes. J. Clin. Investig. 2024, 134, e172883. https://doi.org/10.1172/jci172883.

  • 42.

    Juliano, V.A.L.; Albernaz-Mariano, K.A.; Covre, L.H.H.; et al. Neurobiological intersections of stress and substance use disorders. Front. Neurosci. 2025, 19, 1548372. https://doi.org/10.3389/fnins.2025.1548372.

  • 43.

    Robinson, T.E.; Berridge, K.C. The psychology and neurobiology of addiction: An incentive–sensitization view. Addiction 2000, 95, 91–117. https://doi.org/10.1080/09652140050111681.

  • 44.

    Wand, G.S. The influence of stress on the transition from drug use to addiction. Alcohol Res. Health 2008, 31, 119–136.

  • 45.

    Piazza, P.V.; Le Moal, M. Glucocorticoids as a biological substrate of reward: Physiological and pathophysiological implications. Brain Res. Rev. 1997, 25, 359–372. https://doi.org/10.1016/s0165-0173(97)00025-8.

  • 46.

    Koob, G.F. Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development. Pharmacol. Rev. 2021, 73, 163–201. https://doi.org/10.1124/pharmrev.120.000083.

  • 47.

    Preston, K.L.; Epstein, D.H. Stress in the daily lives of cocaine and heroin users: Relationship to mood, craving, relapse triggers, and cocaine use. Psychopharmacology 2011, 218, 29–37. https://doi.org/10.1007/s00213-011-2183-x.

  • 48.

    Mantsch, J.R.; Baker, D.A.; Funk, D.; et al. Stress-Induced Reinstatement of Drug Seeking: 20 Years of Progress. Neuropsychopharmacology 2016, 41, 335–356. https://doi.org/10.1038/npp.2015.142.

  • 49.

    Everitt, B.J.; Robbins, T.W. Drug Addiction: Updating Actions to Habits to Compulsions Ten Years On. Annu. Rev. Psychol. 2016, 67, 23–50. https://doi.org/10.1146/annurev-psych-122414-033457.

  • 50.

    Schwabe, L.; Dickinson, A.; Wolf, O.T. Stress, habits, and drug addiction: A psychoneuroendocrinological perspective. Exp. Clin. Psychopharmacol. 2011, 19, 53–63. https://doi.org/10.1037/a0022212.

  • 51.

    Hogarth, L. Addiction is driven by excessive goal-directed drug choice under negative affect: Translational critique of habit and compulsion theory. Neuropsychopharmacology 2020, 45, 720–735. https://doi.org/10.1038/s41386-020-0600-8.

  • 52.

    Johnson, S.W.; North, R.A. Opioids excite dopamine neurons by hyperpolarization of local interneurons. J. Neurosci. 1992, 12, 483–488. https://doi.org/10.1523/jneurosci.12-02-00483.1992.

  • 53.

    Kosten, T.; George, T. The Neurobiology of Opioid Dependence: Implications for Treatment. Sci. Pract. Perspect. 2002, 1, 13–20. https://doi.org/10.1151/spp021113.

  • 54.

    Paniccia, J.E.; Vollmer, K.M.; Green, L.M.; et al. Restoration of a paraventricular thalamo-accumbal behavioral suppression circuit prevents reinstatement of heroin seeking. Neuron 2024, 112, 772–785.e9. https://doi.org/10.1016/j.neuron.2023.11.024.

  • 55.

    Liu, Q.M.; Lucas, M.; Badami, F.; et al. Cortical plasticity differences in substance use disorders. Fundam. Res. 2024, 4, 1351–1356. https://doi.org/10.1016/j.fmre.2023.02.015.

  • 56.

    Vuong, C.; Van Uum, S.H.M.; O’Dell, L.E.; et al. The Effects of Opioids and Opioid Analogs on Animal and Human Endocrine Systems. Endocr. Rev. 2010, 31, 98–132. https://doi.org/10.1210/er.2009-0009.

  • 57.

    Fountas, A.; Chai, S.T.; Kourkouti, C.; et al. Mechanisms of Endocrinology: Endocrinology of Opioids. Eur. J. Endocrinol. 2018, 179, R183–R196. https://doi.org/10.1530/eje-18-0270.

  • 58.

    Karavitaki, N.; Bettinger, J.J.; Biermasz, N.; et al. Exogenous Opioids and the Human Endocrine System: An Endocrine Society Scientific Statement. Endocr. Rev. 2024, 45, 773–794. https://doi.org/10.1210/endrev/bnae023.

  • 59.

    Facchinetti, F.; Volpe, A.; Farci, G.; et al. Hypothalamus-pituitary-adrenal axis of heroin addicts. Drug Alcohol Depend. 1985, 15, 361–366. https://doi.org/10.1016/0376-8716(85)90014-6.

  • 60.

    Camí, J.; Gilabert, M.; San, L.; et al. Hypercortisolism after opioid discontinuation in rapid detoxification of heroin addicts. Br. J. Addict. 1992, 87, 1145–1151. https://doi.org/10.1111/j.1360-0443.1992.tb02001.x.

  • 61.

    Zhang, G.F.; Ren, Y.P.; Sheng, L.X.; et al. Dysfunction of the Hypothalamic-Pituitary-Adrenal Axis in Opioid Dependent Subjects: Effects of Acute and Protracted Abstinence. Am. J. Drug Alcohol Abus. 2008, 34, 760–768. https://doi.org/10.1080/00952990802385781.

  • 62.

    Schmidt, A.; Borgwardt, S.; Gerber, H.; et al. Acute Effects of Heroin on Negative Emotional Processing: Relation of Amygdala Activity and Stress-Related Responses. Biol. Psychiatry 2014, 76, 289–296. https://doi.org/10.1016/j.biopsych.2013.10.019.

  • 63.

    Patel, E.; Ben-Shlomo, A. Opioid-induced adrenal insufficiency: Diagnostic and management considerations. Front. Endocrinol. 2024, 14, 1280603. https://doi.org/10.3389/fendo.2023.1280603.

  • 64.

    Kreek, M.J.; Wardlaw, S.L.; Hartman, N.; et al. Circadian rhythms and levels of β-endorphin, ACTH, and cortisol during chronic methadone maintenance treatment in humans. Life Sci. 1983, 33 (Suppl. S1), 409–411. https://doi.org/10.1016/0024-3205(83)90529-5.

  • 65.

    Schluger, J.H.; Bart, G.; Green, M.; et al. Corticotropin-Releasing Factor Testing Reveals a Dose-Dependent Difference in Methadone Maintained vs. Control Subjects. Neuropsychopharmacology 2003, 28, 985–994. https://doi.org/10.1038/sj.npp.1300156.

  • 66.

    Mehranfard, N.; Ghasemi, M.; Saboory, E. Disrupted circadian rhythms and opioid-mediated adverse effects: Bidirectional relationship and putative mechanisms. J. Neuroendocrinol. 2025, 37, e70065. https://doi.org/10.1111/jne.70065.

  • 67.

    Culpepper-Morgan, J.A.; Kreek, M.J. Hypothalamic-pituitary-adrenal axis hypersensitivity to naloxone in opioid dependence: A case of naloxone-induced withdrawal. Metabolism 1997, 46, 130–134. https://doi.org/10.1016/s0026-0495(97)90289-4.

  • 68.

    Gerra, G.; Ceresini, S.; Esposito, A.; et al. Neuroendocrine and behavioural responses to opioid receptor-antagonist during heroin detoxification: Relationship with personality traits. Int. Clin. Psychopharmacol. 2003, 18, 261–269. https://doi.org/10.1097/00004850-200309000-00002.

  • 69.

    Glahn, A.; Heberlein, A.; Dürsteler-MacFarland, K.M.; et al. Atrial Natriuretic Peptide, Arginine Vasopressin Peptide and Cortisol Serum Levels in Opiate-Dependent Patients. Neuropsychobiology 2013, 67, 111–115. https://doi.org/10.1159/000346110.

  • 70.

    McKendrick, G.; Clapham, C.; Zipunnikov, V.; et al. Effects of suvorexant on diurnal cortisol and patient-reported stress during opioid withdrawal in a randomized trial. Psychoneuroendocrinology 2025, 180, 107570. https://doi.org/10.1016/j.psyneuen.2025.107570.

  • 71.

    McNally, G.P.; Akil, H. Role of Corticotropin-Releasing Hormone in the Amygdala and Bed Nucleus of the Stria Terminalis in the Behavioral, Pain Modulatory, and Endocrine Consequences of Opiate Withdrawal. Neuroscience 2002, 112, 605–617. https://doi.org/10.1016/s0306-4522(02)00105-7.

  • 72.

    Watanabe, T.; Nakagawa, T.; Yamamoto, R.; et al. Involvement of noradrenergic system within the central nucleus of the amygdala in naloxone-precipitated morphine withdrawal-induced conditioned place aversion in rats. Psychopharmacology 2003, 170, 80–88. https://doi.org/10.1007/s00213-003-1504-0.

  • 73.

    Smith, R.J.; Aston-Jones, G. Noradrenergic transmission in the extended amygdala: Role in increased drug-seeking and relapse during protracted drug abstinence. Brain Struct. Funct. 2008, 213, 43–61. https://doi.org/10.1007/s00429-008-0191-3.

  • 74.

    Kash, T.L.; Winder, D.G. Neuropeptide Y and corticotropin-releasing factor bi-directionally modulate inhibitory synaptic transmission in the bed nucleus of the stria terminalis. Neuropharmacology 2006, 51, 1013–1022. https://doi.org/10.1016/j.neuropharm.2006.06.011.

  • 75.

    Avegno, E.M.; Middleton, J.W.; Gilpin, N.W. Synaptic GABAergic transmission in the central amygdala (CeA) of rats depends on slice preparation and recording conditions. Physiol. Rep. 2019, 7, e14245. https://doi.org/10.14814/phy2.14245.

  • 76.

    Chartoff, E.; Sawyer, A.; Rachlin, A.; et al. Blockade of kappa opioid receptors attenuates the development of depressive-like behaviors induced by cocaine withdrawal in rats. Neuropharmacology 2012, 62, 167–176. https://doi.org/10.1016/j.neuropharm.2011.06.014.

  • 77.

    Houshyar, H.; Cooper, Z.D.; Woods, J.H. Paradoxical Effects of Chronic Morphine Treatment on the Temperature and Pituitary-Adrenal Responses to Acute Restraint Stress: A Chronic Stress Paradigm. J. Neuroendocrinol. 2001, 13, 862–874. https://doi.org/10.1046/j.1365-2826.2001.00713.x.

  • 78.

    Houshyar, H.; Galigniana, M.D.; Pratt, W.B.; et al. Differential Responsivity of the Hypothalamic-Pituitary-Adrenal Axis to Glucocorticoid Negative-Feedback and Corticotropin Releasing Hormone in Rats Undergoing Morphine Withdrawal: Possible Mechanisms Involved in Facilitated and Attenuated Stress Responses. J. Neuroendocrinol. 2001, 13, 875–886. https://doi.org/10.1046/j.1365-2826.2001.00714.x.

  • 79.

    Houshyar, H.; Gomez, F.; Manalo, S.; et al. Intermittent Morphine Administration Induces Dependence and is a Chronic Stressor in Rats. Neuropsychopharmacology 2003, 28, 1960–1972. https://doi.org/10.1038/sj.npp.1300271.

  • 80.

    Goeldner, C.; Lutz, P.E.; Darcq, E.; et al. Impaired Emotional-Like Behavior and Serotonergic Function During Protracted Abstinence from Chronic Morphine. Biol. Psychiatry 2011, 69, 236–244. https://doi.org/10.1016/j.biopsych.2010.08.021.

  • 81.

    Lutz, P.E.; Reiss, D.; Ouagazzal, A.M.; et al. A history of chronic morphine exposure during adolescence increases despair-like behaviour and strain-dependently promotes sociability in abstinent adult mice. Behav. Brain Res. 2013, 243, 44–52. https://doi.org/10.1016/j.bbr.2012.12.049.

  • 82.

    Carmack, S.A.; Vendruscolo, J.C.M.; McGinn, M.A.; et al. Corticosteroid sensitization drives opioid addiction. Mol. Psychiatry 2022, 27, 2492–2501. https://doi.org/10.1038/s41380-022-01501-1.

  • 83.

    Wang, L.; Shen, M.; Jiang, C.; et al. Parvalbumin Interneurons of Central Amygdala Regulate the Negative Affective States and the Expression of Corticotrophin-Releasing Hormone During Morphine Withdrawal. Int. J. Neuropsychopharmacol. 2016, 19, pyw060. https://doi.org/10.1093/ijnp/pyw060.

  • 84.

    Gregoriou, G.C.; Patel, S.D.; Pyne, S.; et al. Opioid Withdrawal Abruptly Disrupts Amygdala Circuit Function by Reducing Peptide Actions. J. Neurosci. 2023, 43, 1668–1681. https://doi.org/10.1523/jneurosci.1317-22.2022.

  • 85.

    Joëls, M.; Karst, H.; DeRijk, R.; et al. The coming out of the brain mineralocorticoid receptor. Trends Neurosci. 2008, 31, 1–7. https://doi.org/10.1016/j.tins.2007.10.005.

  • 86.

    Datson, N.A.; van den Oever, J.M.E.; Korobko, O.B.; et al. Previous History of Chronic Stress Changes the Transcriptional Response to Glucocorticoid Challenge in the Dentate Gyrus Region of the Male Rat Hippocampus. Endocrinology 2013, 154, 3261–3272. https://doi.org/10.1210/en.2012-2233.

  • 87.

    Navarro-Zaragoza, J.; Hidalgo, J.M.; Laorden, M.L.; et al. Glucocorticoid receptors participate in the opiate withdrawal-induced stimulation of rats NTS noradrenergic activity and in the somatic signs of morphine withdrawal. Br. J. Pharmacol. 2012, 166, 2136–2147. https://doi.org/10.1111/j.1476-5381.2012.01918.x.

  • 88.

    McNally, G.P.; Akil, H. Selective down-regulation of hippocampal glucocorticoid receptors during opiate withdrawal. Mol. Brain Res. 2003, 118, 152–155. https://doi.org/10.1016/s0169-328x(03)00333-4.

  • 89.

    Jaferi, A.; Lane, D.A.; Pickel, V.M. Subcellular plasticity of the corticotropin-releasing factor receptor in dendrites of the mouse bed nucleus of the stria terminalis following chronic opiate exposure. Neuroscience 2009, 163, 143–154. https://doi.org/10.1016/j.neuroscience.2009.06.029.

  • 90.

    García-Carmona, J.A.; Milanés, M.V.; Laorden, M.L. Brain stress system response after morphine-conditioned place preference. Int. J. Neuropsychopharmacol. 2013, 16, 1999–2011. https://doi.org/10.1017/s1461145713000588.

  • 91.

    Lunden, J.W.; Kirby, L.G. Opiate exposure and withdrawal dynamically regulate mRNA expression in the serotonergic dorsal raphe nucleus. Neuroscience 2013, 254, 160–172. https://doi.org/10.1016/j.neuroscience.2013.08.071.

  • 92.

    Schulkin, J.; McEwen, B.S.; Gold, P.W. Allostasis, amygdala, and anticipatory angst. Neurosci. Biobehav. Rev. 1994, 18, 385–396. https://doi.org/10.1016/0149-7634(94)90051-5.

  • 93.

    Keen-Rhinehart, E.; Michopoulos, V.; Toufexis, D.J.; et al. Continuous expression of corticotropin-releasing factor in the central nucleus of the amygdala emulates the dysregulation of the stress and reproductive axes. Mol. Psychiatry 2009, 14, 37–50. https://doi.org/10.1038/mp.2008.91.

  • 94.

    Volavka, J.; Cho, D.; Mallya, A.; et al. Naloxone Increases ACTH and Cortisol Levels in Man. N. Engl. J. Med. 1979, 300, 1056–1057. https://doi.org/10.1056/nejm197905033001817.

  • 95.

    Wand, G.S.; Schumann, H. Relationship between Plasma Adrenocorticotropin, Hypothalamic Opioid Tone, and Plasma Leptin. J. Clin. Endocrinol. Metab. 1998, 83, 2138–2142. https://doi.org/10.1210/jcem.83.6.4900.

  • 96.

    al’Absi, M.; Nakajima, M.; DeAngelis, B.; et al. Blunted opioid regulation of the HPA stress response during nicotine withdrawal: Therapeutic implications. Stress 2021, 24, 529–540. https://doi.org/10.1080/10253890.2020.1823367.

  • 97.

    Koob, G.; Kreek, M.J. Stress, Dysregulation of Drug Reward Pathways, and the Transition to Drug Dependence. Am. J. Psychiatry 2007, 164, 1149–1159. https://doi.org/10.1176/appi.ajp.2007.05030503.

  • 98.

    Fosnocht, A.Q.; Briand, L.A. Substance use modulates stress reactivity: Behavioral and physiological outcomes. Physiol. Behav. 2016, 166, 32–42. https://doi.org/10.1016/j.physbeh.2016.02.024.

  • 99.

    Greenwald, M.K.; Woodcock, E.A.; Moses, T.E.H.; et al. Basal cortisol level modulates stress-induced opioid-seeking behavior. Neurobiol. Stress 2024, 33, 100684. https://doi.org/10.1016/j.ynstr.2024.100684.

  • 100.

    Blaine, S.K.; Sinha, R. Alcohol, stress, and glucocorticoids: From risk to dependence and relapse in alcohol use disorders. Neuropharmacology 2017, 122, 136–147. https://doi.org/10.1016/j.neuropharm.2017.01.037.

  • 101.

    Wemm, S.E.; Sinha, R. Drug-induced stress responses and addiction risk and relapse. Neurobiol. Stress 2019, 10, 100148. https://doi.org/10.1016/j.ynstr.2019.100148.

  • 102.

    Walter, M.; Wiesbeck, G.A.; Degen, B.; et al. Heroin reduces startle and cortisol response in opioid-maintained heroin-dependent patients. Addict. Biol. 2011, 16, 145–151. https://doi.org/10.1111/j.1369-1600.2010.00205.x.

  • 103.

    Xie, P.; Wang, T.J.; Yin, G.; et al. Metabonomic Study of Biochemical Changes in Human Hair of Heroin Abusers by Liquid Chromatography Coupled with Ion Trap-Time of Flight Mass Spectrometry. J. Mol. Neurosci. 2016, 58, 93–101. https://doi.org/10.1007/s12031-015-0655-x.

  • 104.

    Schluger, J.H.; Borg, L.; Ho, A.; et al. Altered HPA Axis Responsivity to Metyrapone Testing in Methadone Maintained Former Heroin Addicts with Ongoing Cocaine Addiction. Neuropsychopharmacology 2001, 24, 568–575. https://doi.org/10.1016/s0893-133x(00)00222-0.

  • 105.

    Walter, M.; Wiesbeck, G.A.; Bloch, N.; et al. Psychobiological responses to drug cues before and after methadone intake in heroin-dependent patients: A pilot study. Eur. Neuropsychopharmacol. 2008, 18, 390–393. https://doi.org/10.1016/j.euroneuro.2008.01.005.

  • 106.

    Yang, J.; Li, J.; Xu, G.; et al. Elevated Hair Cortisol Levels among Heroin Addicts on Current Methadone Maintenance Compared to Controls. PLoS ONE 2016, 11, e0150729. https://doi.org/10.1371/journal.pone.0150729.

  • 107.

    McEwen, B.S. Protection and Damage from Acute and Chronic Stress: Allostasis and Allostatic Overload and Relevance to the Pathophysiology of Psychiatric Disorders. Ann. N. Y. Acad. Sci. 2004, 1032, 1–7. https://doi.org/10.1196/annals.1314.001.

  • 108.

    McEwen, B.S.; Morrison, J.H. The Brain on Stress: Vulnerability and Plasticity of the Prefrontal Cortex over the Life Course. Neuron 2013, 79, 16–29. https://doi.org/10.1016/j.neuron.2013.06.028.

  • 109.

    Cook, S.C.; Wellman, C.L. Chronic stress alters dendritic morphology in rat medial prefrontal cortex. J. Neurobiol. 2004, 60, 236–248. https://doi.org/10.1002/neu.20025.

  • 110.

    Liston, C.M.; Miller, M.M.; Goldwater, D.S.; et al. Stress-Induced Alterations in Prefrontal Cortical Dendritic Morphology Predict Selective Impairments in Perceptual Attentional Set-Shifting. J. Neurosci. 2006, 26, 7870–7874. https://doi.org/10.1523/jneurosci.1184-06.2006.

  • 111.

    Hains, A.B.; Vu, M.A.T.; Maciejewski, P.K.; et al. Inhibition of protein kinase C signaling protects prefrontal cortex dendritic spines and cognition from the effects of chronic stress. Proc. Natl. Acad. Sci. USA 2009, 106, 17957–17962. https://doi.org/10.1073/pnas.0908563106.

  • 112.

    Radley, J.; Rocher, A.; Janssen, W.; et al. Reversibility of apical dendritic retraction in the rat medial prefrontal cortex following repeated stress. Exp. Neurol. 2005, 196, 199–203. https://doi.org/10.1016/j.expneurol.2005.07.008.

  • 113.

    Kalivas, P.W.; Lalumiere, R.T.; Knackstedt, L.; et al. Glutamate transmission in addiction. Neuropharmacology 2009, 56, 169–173. https://doi.org/10.1016/j.neuropharm.2008.07.011.

  • 114.

    Siemsen, B.M.; Denton, A.R.; Parrila-Carrero, J.; et al. Heroin Self-Administration and Extinction Increase Prelimbic Cortical Astrocyte-Synapse Proximity and Alter Dendritic Spine Morphometrics That Are Reversed by N-Acetylcysteine. Cells 2023, 12, 1812. https://doi.org/10.3390/cells12141812.

  • 115.

    Butelman, E.R.; Huang, Y.; Cathomas, F.; et al. Serum cytokines and inflammatory proteins in individuals with heroin use disorder: Potential mechanistically based biomarkers for diagnosis. Transl. Psychiatry 2024, 14, 414. https://doi.org/10.1038/s41398-024-03119-z.

  • 116.

    Green, J.M.; Sundman, M.H.; Chou, Y.H. Opioid-induced microglia reactivity modulates opioid reward, analgesia, and behavior. Neurosci. Biobehav. Rev. 2022, 135, 104544. https://doi.org/10.1016/j.neubiorev.2022.104544.

  • 117.

    Wang, Y.; Singh, A.; Li, G.; et al. Opioid induces increased DNA damage in prefrontal cortex and nucleus accumbens. Pharmacol. Biochem. Behav. 2023, 224, 173535. https://doi.org/10.1016/j.pbb.2023.173535.

  • 118.

    Murlanova, K.; Jouroukhin, Y.; Novototskaya-Vlasova, K.; et al. Loss of Astrocytic µ Opioid Receptors Exacerbates Aversion Associated with Morphine Withdrawal in Mice: Role of Mitochondrial Respiration. Cells 2023, 12, 1412. https://doi.org/10.3390/cells12101412.

  • 119.

    Hejnova, L.; Hronova, A.; Drastichova, Z.; et al. Long-term administration of morphine specifically alters the level of protein expression in different brain regions and affects the redox state. Open Life Sci. 2024, 19, 20220858. https://doi.org/10.1515/biol-2022-0858.

  • 120.

    Klengel, T.; Mehta, D.; Anacker, C.; et al. Allele-specific FKBP5 DNA demethylation mediates gene-childhood trauma interactions. Nat. Neurosci. 2013, 16, 33–41. https://doi.org/10.1038/nn.3275.

  • 121.

    Corradin, O.; Sallari, R.; Hoang, A.T.; et al. Convergence of case-specific epigenetic alterations identify a confluence of genetic vulnerabilities tied to opioid overdose. Mol. Psychiatry 2022, 27, 2158–2170. https://doi.org/10.1038/s41380-022-01477-y.

  • 122.

    Anand, A.; Agarwal, Y.; Gupta, T.; et al. EnsembleAge clock: A reliable and robust epigenetic age clock service reveals epigenetic age acceleration in opioid-overdosed brains. BMC Genom. 2025, 26, 1088. https://doi.org/10.1186/s12864-025-12271-9.

  • 123.

    Shelton, M.A.; Horan, N.; Xue, X.; et al. Sex-Specific Concordance of Striatal Transcriptional Signatures of Opioid Addiction in Human and Rodent Brains. Biol. Psychiatry Glob. Open Sci. 2025, 5, 100476. https://doi.org/10.1016/j.bpsgos.2025.100476.

  • 124.

    McEwen, B.S.; Akil, H. Revisiting the Stress Concept: Implications for Affective Disorders. J. Neurosci. 2020, 40, 12–21. https://doi.org/10.1523/jneurosci.0733-19.2019.

  • 125.

    Hansson, A.C.; Sommer, W.H.; Metsis, M.; et al. Corticosterone Actions on the Hippocampal Brain-Derived Neurotrophic Factor Expression are Mediated by Exon IV Promoter. J. Neuroendocrinol. 2006, 18, 104–114. https://doi.org/10.1111/j.1365-2826.2005.01390.x.

  • 126.

    Lyoo, I.K.; Pollack, M.H.; Silveri, M.M.; et al. Prefrontal and temporal gray matter density decreases in opiate dependence. Psychopharmacology 2006, 184, 139–144. https://doi.org/10.1007/s00213-005-0198-x.

  • 127.

    Liu, H.; Hao, Y.; Kaneko, Y.; et al. Frontal and cingulate gray matter volume reduction in heroin dependence: Optimized voxel-based morphometry. Psychiatry Clin. Neurosci. 2009, 63, 563–568. https://doi.org/10.1111/j.1440-1819.2009.01989.x.

  • 128.

    Yuan, Y.; Zhu, Z.; Shi, J.; et al. Gray matter density negatively correlates with duration of heroin use in young lifetime heroin-dependent individuals. Brain Cogn. 2009, 71, 223–228. https://doi.org/10.1016/j.bandc.2009.08.014.

  • 129.

    Upadhyay, J.; Maleki, N.; Potter, J.; et al. Alterations in brain structure and functional connectivity in prescription opioid-dependent patients. Brain 2010, 133, 2098–2114. https://doi.org/10.1093/brain/awq138.

  • 130.

    King, S.G.; Gaudreault, P.O.; Malaker, P.; et al. Prefrontal-habenular microstructural impairments in human cocaine and heroin addiction. Neuron 2022, 110, 3820–3832.e4. https://doi.org/10.1016/j.neuron.2022.09.011.

  • 131.

    Gaudreault, P.O.; King, S.G.; Huang, Y.; et al. Frontal White Matter Changes and Craving Recovery in Inpatients with Heroin Use Disorder. JAMA Netw. Open 2024, 7, e2451678. https://doi.org/10.1001/jamanetworkopen.2024.51678.

  • 132.

    Yang, W.; Zhang, M.; Tang, F.; et al. Recovery of superior frontal gyrus cortical thickness and resting-state functional connectivity in abstinent heroin users after 8 months of follow-up. Hum. Brain Mapp. 2022, 43, 3164–3175. https://doi.org/10.1002/hbm.25841.

  • 133.

    Savic, I.; Perski, A.; Osika, W. MRI Shows that Exhaustion Syndrome Due to Chronic Occupational Stress is Associated with Partially Reversible Cerebral Changes. Cereb. Cortex 2018, 28, 894–906. https://doi.org/10.1093/cercor/bhw413.

  • 134.

    Henze, G.I.; Konzok, J.; Kudielka, B.M.; et al. Associations between cortisol stress responses and limbic volume and thickness in young adults: An exploratory study. Eur. J. Neurosci. 2023, 58, 3962–3980. https://doi.org/10.1111/ejn.16161.

  • 135.

    Moreno, G.L.; Bruss, J.; Denburg, N.L. Increased perceived stress is related to decreased prefrontal cortex volumes among older adults. J. Clin. Exp. Neuropsychol. 2017, 39, 313–325. https://doi.org/10.1080/13803395.2016.1225006.

  • 136.

    Huang, Y.; Ceceli, A.O.; Kronberg, G.; et al. Association of Cortico-Striatal Engagement During Cue Reactivity, Reappraisal, and Savoring of Drug and Non-Drug Stimuli With Craving in Heroin Addiction. Am. J. Psychiatry 2024, 181, 153–165. https://doi.org/10.1176/appi.ajp.20220759.

  • 137.

    Shi, Z.; Jagannathan, K.; Padley, J.H.; et al. The role of withdrawal in mesocorticolimbic drug cue reactivity in opioid use disorder. Addict. Biol. 2021, 26, e12977. https://doi.org/10.1111/adb.12977.

  • 138.

    Li, Q.; Li, Z.; Li, W.; et al. Disrupted Default Mode Network and Basal Craving in Male Heroin-Dependent Individuals. J. Clin. Psychiatry 2016, 77, e1211–e1217. https://doi.org/10.4088/jcp.15m09965.

  • 139.

    Wen, X.; Yang, W.; Du, Z.; et al. Multimodal frontal neuroimaging markers predict longitudinal craving reduction in abstinent individuals with heroin use disorder. J. Psychiatr. Res. 2024, 177, 1–10. https://doi.org/10.1016/j.jpsychires.2024.06.035.

  • 140.

    Kronberg, G.; Ceceli, A.O.; Huang, Y.; et al. Shared orbitofrontal dynamics to a drug-themed movie track craving and recovery in heroin addiction. Brain 2025, 148, 1778–1788. https://doi.org/10.1093/brain/awae369.

  • 141.

    Moeller, S.J.; Abeykoon, S.; Dhayagude, P.; et al. Neural Correlates of Metacognition Impairment in Opioid Addiction. Biol. Psychiatry Cogn. Neurosci. Neuroimaging 2024, 9, 1211–1221. https://doi.org/10.1016/j.bpsc.2024.07.014.

  • 142.

    Zhao, W.; Duan, F.; Li, X.; et al. Cognitive control in individuals with heroin use disorder after prolonged methadone maintenance treatment. BMC Psychiatry 2025, 25, 78. https://doi.org/10.1186/s12888-025-06523-x.

  • 143.

    Kosten, T.R. Stress and Addiction. Am. J. Psychiatry 2011, 168, 566–568. https://doi.org/10.1176/appi.ajp.2011.11020180.

  • 144.

    Tolomeo, S.; Steele, J.D.; Ekhtiari, H.; et al. Chronic heroin use disorder and the brain: Current evidence and future implications. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2021, 111, 110148. https://doi.org/10.1016/j.pnpbp.2020.110148.

  • 145.

    Lin, T.; Barash, J.A.; Wang, S.; et al. Regular use of opioids and dementia, cognitive measures, and neuroimaging outcomes among UK Biobank participants with chronic non-cancer pain. Alzheimer’s Dement. 2025, 21, e70177. https://doi.org/10.1002/alz.70177.

  • 146.

    Kreek, M.J. Methadone-Related Opioid Agonist Pharmacotherapy for Heroin Addiction: History, Recent Molecular and Neurochemical Research and Future in Mainstream Medicine. Ann. N. Y. Acad. Sci. 2000, 909, 186–216. https://doi.org/10.1111/j.1749-6632.2000.tb06683.x.

  • 147.

    Nava, F.; Caldiroli, E.; Premi, S.; et al. Relationship Between Plasma Cortisol Levels, Withdrawal Symptoms and Craving in Abstinent and Treated Heroin Addicts. J. Addict. Dis. 2006, 25, 9–16. https://doi.org/10.1300/j069v25n02_02.

  • 148.

    Zojaji, F.; Khalesi, A.; Bahrami, A.; et al. Evaluation of Serum Cortisol Levels and Response to Cosyntropin Test in Methadone-treated Opium Addicts. Anesthesiol. Pain Med. 2023, 13, e135206. https://doi.org/10.5812/aapm-135206.

  • 149.

    Nava, F.; Manzato, E.; Lucchini, A. Chronic cannabis use does not affect the normalization of hypothalamic-pituitary-adrenal (HPA) axis induced by methadone in heroin addicts. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2007, 31, 1089–1094. https://doi.org/10.1016/j.pnpbp.2007.03.013.

  • 150.

    Oesterle, T.S.; Xiao, Y.; Bormann, N.L.; et al. Wearable-derived measures of stress physiology in patients with opioid use disorder treated with methadone: A stress-task study in a real-world clinic with healthy controls. Drug Alcohol Depend. Rep. 2026, 20, 100457. https://doi.org/10.1016/j.dadr.2026.100457.

  • 151.

    Bershad, A.K.; Jaffe, J.H.; Childs, E.; et al. Opioid partial agonist buprenorphine dampens responses to psychosocial stress in humans. Psychoneuroendocrinology 2015, 52, 281–288. https://doi.org/10.1016/j.psyneuen.2014.12.004.

  • 152.

    Brar, M.K.; Jain, R.; Bhad, R.; et al. Cortisol/DHEA-S Ratio Normalization by Buprenorphine: Associations with Stress, Coping, and Social Support in Youth with Opioid Use Disorder. J. Psychoact. Drugs 2025, 1–12. https://doi.org/10.1080/02791072.2025.2550288.

  • 153.

    Schwarz, T.; Akartuna, D.; Busch, M.; et al. Challenges for the implementation of injectable opioid agonist treatment: A scoping review. Harm Reduct. J. 2024, 21, 217. https://doi.org/10.1186/s12954-024-01102-x.

  • 154.

    Jaremko, K.M.; Sterling, R.C.; Van Bockstaele, E.J. Psychological and physiological stress negatively impacts early engagement and retention of opioid-dependent individuals on methadone maintenance. J. Subst. Abus. Treat. 2015, 48, 117–127. https://doi.org/10.1016/j.jsat.2014.08.006.

  • 155.

    Sauvé, B.; Koren, G.; Walsh, G.; et al. Measurement of Cortisol in Human Hair as a Biomarker of Systemic Exposure. Clin. Investig. Med. 2007, 30, E183–E191. https://doi.org/10.25011/cim.v30i5.2894.

  • 156.

    Martins-Silva, T.; Martins, R.C.; Murray, J.; et al. Hair cortisol measurement: A systematic review of current practices and a proposed checklist for reporting standards. Psychoneuroendocrinology 2025, 171, 107185. https://doi.org/10.1016/j.psyneuen.2024.107185.

  • 157.

    Luciano, M.T.; Acuff, S.F.; Olin, C.C.; et al. Posttraumatic stress disorder, drinking to cope, and harmful alcohol use: A multivariate meta-analysis of the self-medication hypothesis. J. Psychopathol. Clin. Sci. 2022, 131, 447–456. https://doi.org/10.1037/abn0000764.

  • 158.

    Luo, S.X.; Feaster, D.J.; Liu, Y.; et al. Individual-Level Risk Prediction of Return to Use During Opioid Use Disorder Treatment. JAMA Psychiatry 2024, 81, 45–56. https://doi.org/10.1001/jamapsychiatry.2023.3596.

  • 159.

    Rush, A.J.; Gore-Langton, R.E.; Bart, G.; et al. Tools to implement measurement-based care (MBC) in the treatment of opioid use disorder (OUD): Toward a consensus. Addict. Sci. Clin. Pract. 2024, 19, 14. https://doi.org/10.1186/s13722-024-00446-w.

Share this article:
Download PDF
DOI
10.53941/cna.2026.100016
Issue
Volume 2, Issue 4
How to Cite
Della Rocca, F.; Maremmani, I.; Carbone, M. G.; Maremmani, A. G. I. Stress-Driven Brain Remodeling in Opioid Use Disorder: Toward a Neuroprogressive Model. Clinical Neuropsychopharmacology and Addiction 2026, 2 (4), 16. https://doi.org/10.53941/cna.2026.100016.
RIS
BibTex
Copyright & License
article copyright Image
Copyright (c) 2026 by the authors.
Article Metrics
39
Article Views
0
Citations